To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 169 participants.

Also called NCT01682564

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 169 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01682564
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01682564. Randomized; no masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2014-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure
Acronym
CANTABILE
Condition
Hypertension
Condition
Congestive Heart Failure
Intervention (Drug)
Candemore tablet
Intervention (Drug)
Atacand tablet
Lead sponsor
Chong Kun Dang Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct01682564
Content hash
481126357a70769cfbf784f1685e32ef20b1a0185cf379bf7d26e66e8228c735